PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma.
Loading...
Embargo End Date
ICR Authors
Authors
Mahalingam, P
Smith, S
Lopez, J
Sharma, RK
Millard, T
Thway, K
Fisher, C
Reardon, DA
Jones, R
Nicholson, AG
Cunningham, D
Welsh, L
Sharma, B
Smith, S
Lopez, J
Sharma, RK
Millard, T
Thway, K
Fisher, C
Reardon, DA
Jones, R
Nicholson, AG
Cunningham, D
Welsh, L
Sharma, B
Document Type
Journal Article
Date
2023-01-01
Date Accepted
2023-01-05
Abstract
Myxopapillary ependymoma (MPE) is a primary tumor of the central nervous system (CNS), characteristically an indolent malignancy involving the spinal conus medullaris, Filum terminale or cauda equina. We present a rare case of MPE, recurrent in the pelvic soft tissue with eventual pleural and intra-pulmonary metastasis. Refractory to repeated gross resection, adjuvant radiotherapy, platinum-based chemotherapy and temozolomide exploitation of mutant somatic BRCA1 status with the addition of a poly (ADP-ribose); polymerase inhibitor (PARPi) in a novel combination regimen with olaparib-temozolomide (OT) has achieved stable radiological disease after 10 cycles.
Citation
Rare Tumors, 2023, 15 pp. 20363613231152333 -
Source Title
Rare Tumors
Publisher
SAGE PUBLICATIONS LTD
ISSN
2036-3605
eISSN
2036-3613
2036-3613
2036-3613
Collections
Research Team
Early Phase Drug Develop
Medicine (RMH)
Medicine (RMH)